Clinical trial

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-10-03

PhasePHASE2

Study timeline

Study start (actual)2023-10-03Date precision: day

Registry last updated2026-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic HER2-Negative Breast Carcinomaunresolved

Metastatic Triple-Negative Breast Carcinomaunresolved

Interventions

Biospecimen CollectionPROCEDURE

Computed TomographyPROCEDURE

Magnetic Resonance ImagingPROCEDURE

Biospecimen CollectionPROCEDURE

Sacituzumab GovitecanBIOLOGICAL

Sponsors & collaborators

Vanderbilt-Ingram Cancer Centerlead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

NashvilleTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05770531 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.